WO1993021903A1 - Use of borate-polyol complexes in ophthalmic compositions - Google Patents
Use of borate-polyol complexes in ophthalmic compositions Download PDFInfo
- Publication number
- WO1993021903A1 WO1993021903A1 PCT/US1993/004226 US9304226W WO9321903A1 WO 1993021903 A1 WO1993021903 A1 WO 1993021903A1 US 9304226 W US9304226 W US 9304226W WO 9321903 A1 WO9321903 A1 WO 9321903A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyol
- borate
- water
- aqueous composition
- soluble borate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to the use of borate-polyol complexes in ophthalmic compositions.
- these complexes are useful as buffers and/or antimicrobial agents in aqueous ophthalmic compositions, including those ophthalmic compositions containing polyvinyl alcohol.
- Ophthalmic compositions are generally formulated to have a pH between about 4.0 and 8.0. To achieve a pH in this range and to maintain the pH for optimal stability during the shelf life of the composition, a buffer is often included. Borate is the buffer of choice for use in ophthalmic compositions, since it has some inherent antimicrobial activity and often enhances the activity of antimicrobials;
- borate and PVA form a water-insoluble complex which precipitates out of solution and acts as an irritant in the eye.
- PVA polyvinyl alcohol
- ophthalmic compositions containing PVA are generally buffered with acetate, phosphate or other buffers.
- acetate is a weak buffer (pK j . of about 4.5), so a relatively large amount is needed;
- phosphate is a good buffer but, when used in concentrations generally found in ophthalmic formulations, it reduces the antimicrobial activity of preservatives.
- BAC benzalkonium chloride
- BAC benzalkonium chloride
- thimerosal benzalkonium chloride
- polymeric antimicrobials such as Polyquad® (polyquaternium-1) and Dymed® (polyhexamethylene biguanide) have been used in contact lens care products as disinfectants and preservatives. While these polymeric antimicrobials exhibit a broad spectrum of antimicrobial activity, they generally have relatively weak antifungal activity, especially against Aspergillus niger and Aspergillus fumigatus.
- the ophthalmic compositions of the present invention comprise borate-polyol complexes which have surprisingly been found to have increased antimicrobial activity as compared to boric acid or its salts, particularly with respect to organisms such as A. niger.
- the borate-polyol complexes are formed by mixing boric acid and/or its salts with polyols, such as mannitof, glycerin or propylene glycol, in an aqueous solution.
- the resultant solution may then be used as a buffer and/or antimicrobial agent in aqueous ophthalmic compositions, even where such compositions also contain PVA.
- the borate-polyol complexes of the present invention are also useful in unpreserved saline solutions.
- the borate-polyol complexes of the present invention are particularly useful as adjunctive disinfecting agents in contact lens disinfecting solutions containing monomeric quaternary ammonium compounds (e.g., benzalkonium chloride) or biguanides (e.g., chlorhexidine) or polymeric antimicrobials, such as polymeric quaternary ammonium compounds (e.g., Polyquad ® , Alcon Laboratories, Inc., Fort Worth, Texas) or polymeric biguanides (e.g., Dymed ® , Bausch & Lomb, Rochester, New York).
- monomeric quaternary ammonium compounds e.g., benzalkonium chloride
- biguanides e.g., chlorhexidine
- polymeric antimicrobials such as polymeric quaternary ammonium compounds (e.g., Polyquad ® , Alcon Laboratories, Inc., Fort Worth, Texas) or polymeric biguanides (e.g., Dymed
- compositions of the present invention may optionally contain PVA; such compositions are particularly useful in contact lens care products which are targeted for wearers of rigid gas-permeable contact lenses (RGPs), who often complain of discomfort.
- PVA is a viscosity enhancer and is used extensively in all types of RGP products in order to improve the comfort and wearing time of RGPs.
- PVA is also extensively used as a viscosity enhancer for pharmaceutical ophthalmic compositions such as eye drops, gels or ocular inserts.
- boric acid shall refer to boric acid, salts of boric acid - and other pharmaceutically acceptable borates, or combinations thereof. Most suitable are: boric acid, sodium borate, potassium borate, calcium borate, magnesium borate, manganese borate, and other such borate salts.
- polyol shall refer to any compound having at least two adjacent -OH groups which are not in trans configuration relative to each other.
- the polyols can be linear or circular, substituted or unsubstituted, or mixtures thereof, so long as the resultant complex is water-soluble and pharmaceutically acceptable.
- Such compounds include sugars, sugar alcohols, sugar acids and uronic acids.
- Preferred polyols are sugars, sugar alcohols and sugar acids, including, but not limited to: mannitol, glycerin, propylene glycol and sorbitol.
- Especially preferred polyols are mannitol and glycerin; most preferred is mannitol.
- the water-soluble borate-polyol complexes of the present invention may be formed by mixing borate with the polyol(s) of choice in an aqueous solution. These complexes can be used in conjunction with other known preservatives and disinfectants to meet preservative efficacy and disinfection standards. In such compositions, the molar ratio of borate to polyol is generally between about 1:1 and about 1:10, and is preferably between about 1:1 and about 1:2.5.
- the borate- polyol complexes may also be used in unpreserved salines to meet preservative efficacy standards.
- the molar ratio of borate to polyol is generally between about 1:0.1 and about 1:1, and is especially between about 1:0.25 and about 1:0.75.
- Some borate-polyol complexes, such as potassium borotartrate, are commercially available.
- the borate-polyol complexes are utilized in the compositions of the present invention in an amount between about 0.5 to about 6.0 percent by weight (wt%), preferably between about 1.0 to about 2.5 wt%.
- wt% percent by weight
- the optimum amount will depend upon the complexity of the product, since potential interactions may occur with the other components of a composition. Such optimum amount can be readily determined by one skilled in the formulatory arts.
- compositions of the present invention useful with RGPs or compositions such as eye drops, gels or ocular inserts will preferably also contain PVA or other viscosity-enhancing polymers, such as cellulosic polymers or carboxy vinyl polymers.
- PVA is available in a number of grades, each differing in degree of polymerization, percent of hydrolysis, and residual acetate content. Such differences affect the physical and chemical behavior of the different grades. PVA can be divided into two broad categories, i.e., completely hydrolyzed and partially hydrolyzed. Those containing 4% residual acetate content or less are referred to as completely hydrolyzed. Partially hydrolyzed grades usually contain 20% or more residual acetate.
- compositions of the present invention generally contain such types of PVA at a concentration less than about 10.0 wt%, preferably between about 0.1 and about 1.4 wt% and most preferably at a concentration of about 0.75 wt%.
- the water-soluble borate-polyol complexes of the present invention may be prepared as illustrated below.
- Formulations A - H were prepared as follows. Tubular, labeled and calibrated 150 milliliter (mL) beakers were each filled with about 90 mL of purified water. Boric acid, sodium borate and mannitol or glycerin were then added and dissolved by stirring the solution for about 25 minutes. At this time, disodium EDTA (ethylene diamine tetraacetic acid) was added with stirring. Purified water was added to bring the solutions almost to 100% (100 mL), pH was adjusted to approximately 7.4 and the osmolality was measured. Polyquad® was then added and the volume brought to 100% by the addition of purified water. pH was again measured and adjusted, if necessary, and the osmolality was measured again.
- EDTA ethylene diamine tetraacetic acid
- the osmolality can be adjusted by incorporating polyol with OH groups in trans position, sodium chloride, potassium chloride, calcium chloride or other osmolality building agents which are generally acceptable in ophthalmic formulations and known to those skilled in the art.
- Aqueous ophthalmic compositions of the present invention may be prepared using the formulations illustrated below.
- Formulations 1 - 9 were prepared as follows.
- a first solution (Solution A) was prepared by adding 500 mL of warm purified water to a calibrated two liter aspirator bottle equipped with a magnetic stirrer. PVA and hydroxyethyl cellulose were then added to Solution A and the contents dispersed by stirring. After dispersal of the polymers, a filter assembly was attached to the aspirator bottle (142 mm Millipore filter holder with 0.2 ⁇ filter), and this whole apparatus autoclaved at 121°C for 30 minutes. Solution A with the filter assembly attached was then allowed to cool to room temperature with stirring.
- a second solution (Solution B), was prepared in a 500 mL beaker containing 300 mL of purified water by adding boric acid, sodium borate and mannitol and dissolving the contents by stirring for 25 minutes. Edetate disodium, sodium chloride, preservatives and other osmolality-building agents, as necessary, were added to Solution B and the contents dissolved with stirring. Solution B was then sterile filtered into the aspirator bottle containing Solution A. The pH of the resultant solution was then adjusted and the volume brought to 100% by sterile filtering purified water.
- compositions of the present invention may also be prepared using the procedure detailed in Example 2.
- Formulations A and B are shown in the following table.
- Formulations A and B were tested against FDA challenge organisms. The log reductions after 1 hour are tabulated below:
- Formulation B (containing borate-polyol complex) has a broader spectrum of activity than Formulation A (containing phosphate buffer), and has greater activity against certain organisms, such as A. niger.
- Formulation C met the BP standards for preservative efficacy against A. niger, while Formulation D failed to meet the BP standards.
- Formulation samples were inoculated with known levels of A. niger and sampled at predetermined intervals to determine if the system was capable of killing or inhibiting the propagation of organisms introduced into the products.
- Formulations E and F are shown in the following table.
Abstract
Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical borate buffers and unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination. In addition, use of the borate-polyol complexes avoids the incompatibility problem typically associated with the combination of borate buffer and polyvinyl alcohol; therefore, the compositions disclosed herein may also contain polyvinyl alcohol.
Description
USE OF BORATE-POLYOL COMPLEXES IN OPHTHALMIC COMPOSITIONS
'* Cross-Reference to Related Applications
This is a continuation-in-part of U.S. Patent Application Serial No. 07/879,435 filed May 6, 1992.
5 Background of the Invention
This invention relates to the use of borate-polyol complexes in ophthalmic compositions. In particular, these complexes are useful as buffers and/or antimicrobial agents in aqueous ophthalmic compositions, including those ophthalmic compositions containing polyvinyl alcohol.
10 Ophthalmic compositions are generally formulated to have a pH between about 4.0 and 8.0. To achieve a pH in this range and to maintain the pH for optimal stability during the shelf life of the composition, a buffer is often included. Borate is the buffer of choice for use in ophthalmic compositions, since it has some inherent antimicrobial activity and often enhances the activity of antimicrobials;
15 however, when polyvinyl alcohol (PVA) is also an ingredient in the composition, borate and PVA form a water-insoluble complex which precipitates out of solution and acts as an irritant in the eye. This incompatibility of borate and PVA in contact lens solutions is well-known, and has been discussed, for example, in an article by P. L. Rakow in Contact Lens Forum. (June 1988), pages 41-46. Moreover, borate
20 buffer cannot be effectively used below pH 7.0 due to its low buffering capacity to lower pH.
Since borate is incompatible with PVA, ophthalmic compositions containing PVA are generally buffered with acetate, phosphate or other buffers. There are disadvantages to using these alternative buffers: for example, acetate is a weak
buffer (pKj. of about 4.5), so a relatively large amount is needed; on the other hand, phosphate is a good buffer but, when used in concentrations generally found in ophthalmic formulations, it reduces the antimicrobial activity of preservatives.
It is welf known that small organic compounds, such as benzalkonium chloride (BAC), chlorhexidine, thimerosal have excellent antimicrobial activity; however, it is now known that these small organic antimicrobials are often toxic to the sensitive tissues of the eye and can accumulate in contact lenses, particularly soft, hydrophilic contact lenses- More recently, polymeric antimicrobials such as Polyquad® (polyquaternium-1) and Dymed® (polyhexamethylene biguanide) have been used in contact lens care products as disinfectants and preservatives. While these polymeric antimicrobials exhibit a broad spectrum of antimicrobial activity, they generally have relatively weak antifungal activity, especially against Aspergillus niger and Aspergillus fumigatus.
A need therefore exists for ophthalmic compositions which have an optimal pH for stability and efficacy, but whose antimicrobial efficacy is not compromised.
Summary of the Invention
This invention provides such ophthalmic compositions. The ophthalmic compositions of the present invention comprise borate-polyol complexes which have surprisingly been found to have increased antimicrobial activity as compared to boric acid or its salts, particularly with respect to organisms such as A. niger.
Moreover, these complexes unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination.
The borate-polyol complexes are formed by mixing boric acid and/or its salts with polyols, such as mannitof, glycerin or propylene glycol, in an aqueous solution. The resultant solution may then be used as a buffer and/or antimicrobial agent in
aqueous ophthalmic compositions, even where such compositions also contain PVA. The borate-polyol complexes of the present invention are also useful in unpreserved saline solutions.
The borate-polyol complexes of the present invention are particularly useful as adjunctive disinfecting agents in contact lens disinfecting solutions containing monomeric quaternary ammonium compounds (e.g., benzalkonium chloride) or biguanides (e.g., chlorhexidine) or polymeric antimicrobials, such as polymeric quaternary ammonium compounds (e.g., Polyquad®, Alcon Laboratories, Inc., Fort Worth, Texas) or polymeric biguanides (e.g., Dymed®, Bausch & Lomb, Rochester, New York).
The compositions of the present invention may optionally contain PVA; such compositions are particularly useful in contact lens care products which are targeted for wearers of rigid gas-permeable contact lenses (RGPs), who often complain of discomfort. PVA is a viscosity enhancer and is used extensively in all types of RGP products in order to improve the comfort and wearing time of RGPs.
PVA is also extensively used as a viscosity enhancer for pharmaceutical ophthalmic compositions such as eye drops, gels or ocular inserts.
Detailed Description of the Invention
As used herein, the term "borate" shall refer to boric acid, salts of boric acid - and other pharmaceutically acceptable borates, or combinations thereof. Most suitable are: boric acid, sodium borate, potassium borate, calcium borate, magnesium borate, manganese borate, and other such borate salts.
As used herein, and unless otherwise indicated, the term "polyol" shall refer to any compound having at least two adjacent -OH groups which are not in trans configuration relative to each other. The polyols can be linear or circular, substituted or unsubstituted, or mixtures thereof, so long as the resultant complex
is water-soluble and pharmaceutically acceptable. Such compounds include sugars, sugar alcohols, sugar acids and uronic acids. Preferred polyols are sugars, sugar alcohols and sugar acids, including, but not limited to: mannitol, glycerin, propylene glycol and sorbitol. Especially preferred polyols are mannitol and glycerin; most preferred is mannitol.
The water-soluble borate-polyol complexes of the present invention may be formed by mixing borate with the polyol(s) of choice in an aqueous solution. These complexes can be used in conjunction with other known preservatives and disinfectants to meet preservative efficacy and disinfection standards. In such compositions, the molar ratio of borate to polyol is generally between about 1:1 and about 1:10, and is preferably between about 1:1 and about 1:2.5. The borate- polyol complexes may also be used in unpreserved salines to meet preservative efficacy standards. In these unpreserved salines, the molar ratio of borate to polyol is generally between about 1:0.1 and about 1:1, and is especially between about 1:0.25 and about 1:0.75. Some borate-polyol complexes, such as potassium borotartrate, are commercially available.
The borate-polyol complexes are utilized in the compositions of the present invention in an amount between about 0.5 to about 6.0 percent by weight (wt%), preferably between about 1.0 to about 2.5 wt%. The optimum amount, however, will depend upon the complexity of the product, since potential interactions may occur with the other components of a composition. Such optimum amount can be readily determined by one skilled in the formulatory arts.
The compositions of the present invention useful with RGPs or compositions such as eye drops, gels or ocular inserts will preferably also contain PVA or other viscosity-enhancing polymers, such as cellulosic polymers or carboxy vinyl polymers. PVA is available in a number of grades, each differing in degree of polymerization, percent of hydrolysis, and residual acetate content. Such differences affect the physical and chemical behavior of the different grades. PVA can be divided into two broad categories, i.e., completely hydrolyzed and partially
hydrolyzed. Those containing 4% residual acetate content or less are referred to as completely hydrolyzed. Partially hydrolyzed grades usually contain 20% or more residual acetate. The molecular weight of PVA's vary from 20,000 to 200,000. In general, PVA used in ophthalmic products has an average molecular weight in the range of 30,000 to 100,000 with 11% to 15% residual acetate. Compositions of the present invention generally contain such types of PVA at a concentration less than about 10.0 wt%, preferably between about 0.1 and about 1.4 wt% and most preferably at a concentration of about 0.75 wt%.
EXAMPLE 1
The water-soluble borate-polyol complexes of the present invention may be prepared as illustrated below.
Formulations A - H were prepared as follows. Tubular, labeled and calibrated 150 milliliter (mL) beakers were each filled with about 90 mL of purified water. Boric acid, sodium borate and mannitol or glycerin were then added and dissolved by stirring the solution for about 25 minutes. At this time, disodium EDTA (ethylene diamine tetraacetic acid) was added with stirring. Purified water
was added to bring the solutions almost to 100% (100 mL), pH was adjusted to approximately 7.4 and the osmolality was measured. Polyquad® was then added and the volume brought to 100% by the addition of purified water. pH was again measured and adjusted, if necessary, and the osmolality was measured again.
It is not always necessary to have an isotonic solution; however, if there is a need to have an isotonic solution, the osmolality can be adjusted by incorporating polyol with OH groups in trans position, sodium chloride, potassium chloride, calcium chloride or other osmolality building agents which are generally acceptable in ophthalmic formulations and known to those skilled in the art.
EXAMPLE 2
Aqueous ophthalmic compositions of the present invention may be prepared using the formulations illustrated below.
Formulations 1 - 9 were prepared as follows. A first solution (Solution A) was prepared by adding 500 mL of warm purified water to a calibrated two liter aspirator bottle equipped with a magnetic stirrer. PVA and hydroxyethyl cellulose were then added to Solution A and the contents dispersed by stirring. After dispersal of the polymers, a filter assembly was attached to the aspirator bottle (142 mm Millipore filter holder with 0.2 μ filter), and this whole apparatus autoclaved at 121°C for 30 minutes. Solution A with the filter assembly attached was then allowed to cool to room temperature with stirring. A second solution (Solution B), was prepared in a 500 mL beaker containing 300 mL of purified water by adding boric acid, sodium borate and mannitol and dissolving the contents by stirring for 25 minutes. Edetate disodium, sodium chloride, preservatives and other osmolality-building agents, as necessary, were added to Solution B and the contents dissolved with stirring. Solution B was then sterile filtered into the aspirator bottle containing Solution A. The pH of the resultant solution was then adjusted and the volume brought to 100% by sterile filtering purified water.
EXAMPLE 3
The following ophthalmic compositions of the present invention may also be prepared using the procedure detailed in Example 2.
EXAMPLE 4
The following is a typical wetting and soaking composition of the present invention for use with RGPs.
In a suitable container containing approximately 30% of the final volume of purified water, PVA and HEC were added and dispersed. This solution was then autoclaved. The solution was allowed to cool to room temperature with stirring. In a separate container, containing approximately 50% of the final volume of purified water, boric acid and sodium borate were added, and dissolved, followed by mannitol. This second solution was then stirred for about 30 minutes, then potassium chloride, calcium chloride, magnesium chloride, sodium chloride, polysorbate 80 and Polyquad® were added, with stirring. The second solution was then added to the first solution via a 0.2 μ filter. Last, the pH was adjusted to 7.4 and the volume brought to 100% with purified water.
EXAMPLE 5
The following is a typical daily cleaner composition of the present invention for use with RGPs and may be prepared in a manner similar to that detailed in Example 4.
INGREDIENT AMOUNT CwtZ)
Nylon 11 2.50
Dextran 70 6.0
Sodium borate 0.25
Boric acid 0.50 Miracare® 2MCA 0.50
PDMA-1 0.15
Propylene glycol 10.0
Polyquad® 0.0055
EDTA 0.10 Mannitof 1.20
NaOH and/or HCI pH 7.4 '
Purified water q.s.
EXAMPLE 6
The following is a typical wetting and soaking composition of the present invention which may be prepared in a manner similar to that detailed in Example 4.
INGREDIENT AMOUNT (wt%) Hydroxypropyl 0.72 methylcellulose (Methocel® E4M)
Mannitol 1.0
Sodium borate 0.11 Boric acid 0.35
Sodium chloride 0.19
Polyquad® 0.0011
EDTA 0.10
NaOH and/or HCI pH 7.4 Purified water q.s.
EXAMPLE 7
The following is a typical comfort drop composition of the present invention which may be prepared in a manner similar to that detailed in Example 4.
EXAMPLE 8
The following is a typical RGP cleaner composition of the present invention which may be prepared in a manner similar to that detailed in Example 4..
EXAMPLE 9
The following is a typical RGP wetting and/or soaking composition of the present invention., which may be prepared in a manner similar to that detailed in Example 4.
EXAMPLE 10
The following study compared the antimicrobial preservative efficacy of two wetting, soaking and disinfecting solutions: one containing phosphate buffer (Formulation A); and the other containing a borate-polyol complex of the present invention (Formulation B).
Formulations A and B are shown in the following table.
Formulations A and B were tested against FDA challenge organisms. The log reductions after 1 hour are tabulated below:
The results shown above indicate that Formulation B (containing borate-polyol complex) has a broader spectrum of activity than Formulation A (containing phosphate buffer), and has greater activity against certain organisms, such as A. niger.
EXAMPLE 11
The following study compared the antimicrobial preservative efficacy of two unpreserved saline solutions identical except that one contained a borate-polyol complex of the present invention (Formulation C) and the other contained the conventional borate buffer (Formulation D).
An organism challenge approach based on the British Pharmacopoeia ("BP") 1988 Test for Efficacy of Preservatives in Pharmaceutical Products was used to evaluate the antimicrobial preservative efficacy of Formulations C and D. Formulation samples were inoculated with known levels of A. niger and sampled at predetermined intervals to determine if the system was capable of killing or inhibiting the propagation of organisms introduced into the products.
Formulations C and D are shown in the following table.
The results indicated that there was a 3.1 log reduction of A. niger with Formulation C and only 1.2 log reduction with Formulation D after 7 days.
Formulation C met the BP standards for preservative efficacy against A. niger, while Formulation D failed to meet the BP standards.
EXAMPLE 12
The following study compared the antimicrobial preservative efficacy of two disinfecting solutions identical except that one contained a borate-polyol complex of the present invention (Formulation E) and the other contained the conventional borate buffer (Formulation F).
An organism challenge approach based on the BP 1988 Test for Efficacy of Preservatives in Pharmaceutical Products was used to evaluate the antimicrobial preservative efficacy of Formulations E and F. Formulation samples were inoculated with known levels of A. niger and sampled at predetermined intervals to determine if the system was capable of killing or inhibiting the propagation of organisms introduced into the products.
Formulations E and F are shown in the following table.
The results indicate that there was a 2.1 log reduction of A. niger with Formulation E and-only 1.1 log reduction with Formulation F after 7 days. Formulation E met the BP standards for preservative efficacy against A. niger, while Formulation F failed to meet the BP standards.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims
1. An aqueous ophthalmic composition comprising between about 0.5 and about 6.0 wt% of a water-soluble borate-polyol complex.
2. The aqueous composition of claim 1 , wherein the water-soluble borate-polyol complex is present at a concentration between about 1.0 and 2.5 wt%.
3. The aqueous composition of claim 1 , wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.1 and about 1:10.
4. The aqueous composition of claim 3, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.25 and about 1:2.5.
5. The aqueous composition of claim 1 , wherein the water-soluble borate-polyol complex comprises a polyol selected from the group consisting of sugars, sugar alcohols and sugar acids.
6. The aqueous composition of claim 2, wherein the polyol is selected from the group consisting of mannitol, glycerin, propylene glycol and sorbitol.
7. The aqueous composition of claim 6, wherein the polyol is selected from the group consisting of mannitol and glycerin.
8. The aqueous composition of claim 7, wherein the polyol is mannitol.
9. The aqueous composition of claim 1 , further comprising less than or equal to about 10 wt% of a viscosity-enhancing polymer selected from the group consisting of: polyvinyl alcohol, cellulosic polymers, and carboxy vinyl polymers.
10. The aqueous composition of claim 9, wherein the viscosity-enhancing polymer comprises polyvinyl alcohol.
11. The aqueous composition of claim 9, wherein the polyvinyl alcohol is present at a concentration between about 0.1 and about 1.4 wt%.
12. The aqueous composition of claim 1, further comprising an ophthalmically acceptable antimicrobial agent.
13. The aqueous composition of claim 1, wherein the ophthalmically acceptable antimicrobial agent is selected from the group consisting of: monomeric and polymeric quaternary ammonium compounds and their ophthalmically acceptable salts, monomeric and polymeric biguanides and their ophthalmically acceptable salts, and combinations thereof.
14. A method of preparing an aqueous ophthalmic composition, comprising the steps of preparing a water-soluble borate-polyol complex by mixing borate and a polyol together in an aqueous solvent and adding polyvinyl alcohol thereto.
15. The method of claim 14, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.1 and about 1:10.
16. The method of claim 15, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1.0.25 and about 1:2.5.
17. The method of claim 14, wherein the concentration of the water- soluble borate-polyol complex in the final composition is between about 0.5 and about 3.0 wt%.
18. The method of claim 17, wherein the concentration of the water- soluble borate-polyol complex in the final composition is between about 1.0 and
% about 2.0 wt%.
19. The method of claim 14, wherein the water-soluble borate-polyol
5 complex comprises a polyol selected from the group consisting of sugars, sugar alcohols and sugar acids.
20. The method of claim 19, wherein the polyol is selected from the group consisting of mannitol, glycerin, propylene glycol and sorbitol.
21. The method of claim 20, wherein the polyol is selected from the group 10 consisting of mannitol and glycerin.
22. The method of claim 21 , wherein the polyol is mannitol.
23. Use of a water-soluble borate-polyol complex as a buffering agent for aqueous ophthalmic compositions.
24. Use of a water-soluble borate-polyol complex as an ophthalmic 15 antimicrobial agent.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69333850T DE69333850T3 (en) | 1992-05-06 | 1993-05-04 | APPLICATION OF BORAL-POLYOL COMPLEXES FOR OPHTHALMIC DRUG COMPOSITIONS |
| EP93911061A EP0639070B2 (en) | 1992-05-06 | 1993-05-04 | Use of borate-polyol complexes in ophthalmic compositions |
| DK93911061.5T DK0639070T4 (en) | 1992-05-06 | 1993-05-04 | Use of borate-polyol complexes for ophthalmic preparations |
| AT93911061T ATE300936T1 (en) | 1992-05-06 | 1993-05-04 | APPLICATION OF BORAL-POLYOL COMPLEXES FOR OPHTHALMIC MEDICINAL COMPOSITIONS |
| AU42336/93A AU674852B2 (en) | 1992-05-06 | 1993-05-04 | Use of borate-polyol complexes in ophthalmic compositions |
| JP51960893A JP3337218B2 (en) | 1992-05-06 | 1993-05-04 | Use of a borate-polyol complex in ophthalmic compositions |
| HK98112850A HK1011615A1 (en) | 1992-05-06 | 1998-12-04 | Use of borate-polyol complexes in ophthalmic compositions. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87943592A | 1992-05-06 | 1992-05-06 | |
| US07/879,435 | 1992-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993021903A1 true WO1993021903A1 (en) | 1993-11-11 |
Family
ID=25374152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/004226 WO1993021903A1 (en) | 1992-05-06 | 1993-05-04 | Use of borate-polyol complexes in ophthalmic compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5342620A (en) |
| EP (1) | EP0639070B2 (en) |
| JP (2) | JP3337218B2 (en) |
| AT (1) | ATE300936T1 (en) |
| AU (1) | AU674852B2 (en) |
| CA (1) | CA2132826C (en) |
| DE (1) | DE69333850T3 (en) |
| DK (1) | DK0639070T4 (en) |
| ES (1) | ES2246491T5 (en) |
| HK (1) | HK1011615A1 (en) |
| WO (1) | WO1993021903A1 (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013050A1 (en) * | 1993-11-12 | 1995-05-18 | Ciba-Geigy Ag | Ophthalmic formulation useful in the treatment of dry eye syndrom |
| WO1996003484A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
| WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
| EP0923950A2 (en) * | 1997-12-18 | 1999-06-23 | Tomey Corporation | Liquid agent for contact lens |
| US6143799A (en) * | 1992-05-06 | 2000-11-07 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| WO2003026420A1 (en) * | 2001-09-17 | 2003-04-03 | Menicon Co., Ltd. | Bactericidal solutions |
| WO2005093102A2 (en) * | 2004-03-11 | 2005-10-06 | Surmodics, Inc. | Array print buffers |
| EP1642568A1 (en) * | 2004-08-03 | 2006-04-05 | Prontomed GmbH | Mouthwash |
| WO2009151974A1 (en) * | 2008-06-09 | 2009-12-17 | Alcon Research, Ltd. | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| WO2009117242A3 (en) * | 2008-03-17 | 2010-02-04 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| WO2012026609A1 (en) | 2010-08-27 | 2012-03-01 | わかもと製薬株式会社 | Aqueous composition for ophthalmic administration |
| US8563011B2 (en) * | 1996-12-13 | 2013-10-22 | Alcon Research, Ltd. | Use of low molecular weight amino alcohols in ophthalmic compositions |
| US8785497B2 (en) | 2009-04-17 | 2014-07-22 | Alcon Research, Ltd. | Aqueous ophthalmic compositions containing anionic therapeutic agents |
| US9044484B2 (en) | 2009-06-19 | 2015-06-02 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| EP2066300B1 (en) | 2006-09-28 | 2015-06-17 | Alcon Research, Ltd. | Self-preserved aqueous pharmaceutical compositions |
| EP2796138B1 (en) | 1998-09-30 | 2016-08-17 | Alcon Pharmaceuticals Limited | Antibiotic compositions for treatment of conjunctivitis |
| CN111821261A (en) * | 2019-07-23 | 2020-10-27 | 尼科斯眼药公司 | Method for preparing sterile ophthalmic aqueous fluticasone propionate A-type nanocrystal suspension |
| EP3946311A4 (en) * | 2019-03-26 | 2022-12-28 | Martin Uram | Anesthetic composition and method of anesthetizing the eye |
| US11826347B2 (en) | 2018-03-27 | 2023-11-28 | Martin Uram | Anesthetic composition and method of anesthetizing the eye |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246491T5 (en) * | 1992-05-06 | 2011-01-31 | Alcon Laboratories, Inc. | USE OF BORATE-POLYOL COMPLEXES IN OPHTHALM COMPOSITIONS. |
| US5603929A (en) * | 1994-11-16 | 1997-02-18 | Alcon Laboratories, Inc. | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| JP3698832B2 (en) * | 1996-10-08 | 2005-09-21 | 株式会社メニコン | Contact lens solution |
| EP1203808B1 (en) | 1997-07-29 | 2004-09-29 | Alcon Laboratories, Inc. | Conditioning solutions for hard contact lens care |
| JP4536175B2 (en) * | 1998-09-18 | 2010-09-01 | 日油株式会社 | Preservative composition |
| CA2395866C (en) | 2000-01-25 | 2009-10-13 | Alcon, Inc. | Ophthalmic anti-allergy compositions suitable for use with contact lenses |
| JP2010031052A (en) * | 2002-04-08 | 2010-02-12 | Lion Corp | Composition for ophthalmic use and antiseptic composition for ophthalmology preparation |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| WO2004082673A1 (en) * | 2003-03-20 | 2004-09-30 | Menicon Co. Ltd. | Liquid ophthalmic composition |
| JP2005035969A (en) * | 2003-06-25 | 2005-02-10 | Lion Corp | Ophthalmic composition and method for stabilization thereof |
| US20050009836A1 (en) * | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| US20050129770A1 (en) * | 2003-12-11 | 2005-06-16 | Alcon, Inc. | Ophthalmic compositions containing a PVA/borate gelling system |
| US7022740B2 (en) * | 2004-04-29 | 2006-04-04 | Leonard Mackles | Lubricious ophthalmic solutions |
| CA2505836C (en) * | 2004-05-06 | 2013-08-27 | Alcon Inc. | Topical brimonidine tartrate formulations that lack chlorine dioxide |
| US20080307751A1 (en) * | 2004-10-01 | 2008-12-18 | Newman Stephen D | Contact Lens Package Solution |
| US20070059274A1 (en) * | 2004-12-01 | 2007-03-15 | Bahram Asgharian | Ophthalmic compositions containing a PVA/borate gelling system |
| JP5108234B2 (en) * | 2005-02-07 | 2012-12-26 | 日本特殊陶業株式会社 | Micro heater and sensor |
| US20060229219A1 (en) * | 2005-04-11 | 2006-10-12 | Advanced Medical Optics, Inc. | Borate-polyol mixtures as a buffering system |
| WO2006138709A2 (en) | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
| US20070297990A1 (en) * | 2006-06-27 | 2007-12-27 | Shah Mandar V | Self-preserving composition |
| TWI394564B (en) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | Self-preserved aqueous pharmaceutical compositions |
| JP2008094780A (en) * | 2006-10-13 | 2008-04-24 | Nippon Tenganyaku Kenkyusho:Kk | Aqueous ophthalmic preparation of levobunolol hydrochloride |
| US8138156B2 (en) * | 2006-10-18 | 2012-03-20 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
| US20080110770A1 (en) * | 2006-11-10 | 2008-05-15 | Bausch & Lomb Incorporated | Packaging solutions |
| TWI434926B (en) * | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | Use of peo-pbo block copolymers in ophthalmic compositions |
| US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US8609634B2 (en) * | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US8629099B2 (en) * | 2008-03-25 | 2014-01-14 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising a dipeptide |
| TWI454289B (en) * | 2008-04-03 | 2014-10-01 | Alcon Res Ltd | Use of cis-diol-containing polymer to inhibit the uptake of cationic biocides into hydrogel biomaterials |
| US8093352B2 (en) * | 2008-08-05 | 2012-01-10 | Alcon Research, Ltd. | Polyalkylene oxide polyquaternary ammonium biocides |
| US8431751B1 (en) | 2008-12-24 | 2013-04-30 | Alcon Research, Ltd. | Polymeric quaternary ammonium compounds with vicinal hydroxy groups |
| TWI547522B (en) * | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | Ethyleneoxide butyleneoxide block copolymer compositions |
| WO2011153349A1 (en) | 2010-06-02 | 2011-12-08 | Alcon Research, Ltd. | Ophthalmic compositions comprising pbo-peo-pbo block copolymers |
| TWI544922B (en) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | High concentration olopatadine ophthalmic composition |
| JP2013129618A (en) * | 2011-12-21 | 2013-07-04 | Nippon Tenganyaku Kenkyusho:Kk | Levofloxacin-containing water liquid medicine that improves antiseptic efficacy and physical properties |
| US8664180B2 (en) | 2012-02-06 | 2014-03-04 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
| US8324171B1 (en) | 2012-02-06 | 2012-12-04 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
| US20220015366A1 (en) | 2018-11-08 | 2022-01-20 | Hwang Hsing Chen | Tris-substituted biguanide compounds and their uses |
| WO2023013627A1 (en) * | 2021-08-06 | 2023-02-09 | 株式会社大塚製薬工場 | Disinfecting composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2230358A2 (en) * | 1973-05-25 | 1974-12-20 | Fisons Ltd | Cromoglycate contg. solns. - contg. a second therapeutically active cpd. e.g. an antihistamine |
| EP0109561A1 (en) * | 1982-10-27 | 1984-05-30 | Rorer International (Overseas) Inc. | Celiprolol for the treatment of glaucoma |
| EP0436726A1 (en) * | 1989-08-03 | 1991-07-17 | Eisai Co., Ltd. | Method of photostabilizing eyewash |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
| US4581379A (en) * | 1976-03-11 | 1986-04-08 | Nelson Research & Development Co. | Contact lens preserving solution |
| JPS5959619A (en) * | 1982-09-28 | 1984-04-05 | Sunstar Inc | Eye drop |
| US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
| US4748189A (en) * | 1985-04-19 | 1988-05-31 | Ciba-Geigy Corporation | Ophthalmic solutions and methods for improving the comfort and safety of contact lenses |
| JPS62913A (en) * | 1985-06-26 | 1987-01-06 | Lion Corp | Cleaner for contact lens |
| US5032392A (en) * | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
| US5141665A (en) * | 1987-03-31 | 1992-08-25 | Sherman Laboratories, Inc. | Cleaning, conditioning, storing and wetting system and method for rigid gas permeable contact lenses and other contact lenses |
| US4960799A (en) * | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
| US5035859A (en) * | 1989-11-21 | 1991-07-30 | Schering Corporation | Contact lens disinfecting system |
| JP3058656B2 (en) * | 1990-06-18 | 2000-07-04 | トーメー産業株式会社 | Contact lens solution composition and method for cleaning or storing contact lenses using the same |
| JPH0775620B2 (en) † | 1991-04-08 | 1995-08-16 | トーメー産業株式会社 | Liquid formulation for hydrous contact lens and method for washing hydrous contact lens |
| JP3146218B2 (en) * | 1991-07-09 | 2001-03-12 | ライオン株式会社 | Eye drops |
| JP3346586B2 (en) * | 1991-08-29 | 2002-11-18 | 富山化学工業株式会社 | Pharmaceutical composition containing pyridonecarboxylic acid or salt thereof and method for stabilizing solution of pyridonecarboxylic acid or salt thereof |
| ES2246491T5 (en) * | 1992-05-06 | 2011-01-31 | Alcon Laboratories, Inc. | USE OF BORATE-POLYOL COMPLEXES IN OPHTHALM COMPOSITIONS. |
-
1993
- 1993-05-04 ES ES93911061T patent/ES2246491T5/en not_active Expired - Lifetime
- 1993-05-04 DK DK93911061.5T patent/DK0639070T4/en active
- 1993-05-04 WO PCT/US1993/004226 patent/WO1993021903A1/en active IP Right Grant
- 1993-05-04 EP EP93911061A patent/EP0639070B2/en not_active Expired - Lifetime
- 1993-05-04 DE DE69333850T patent/DE69333850T3/en not_active Expired - Lifetime
- 1993-05-04 JP JP51960893A patent/JP3337218B2/en not_active Expired - Lifetime
- 1993-05-04 CA CA002132826A patent/CA2132826C/en not_active Expired - Lifetime
- 1993-05-04 AT AT93911061T patent/ATE300936T1/en active
- 1993-05-04 AU AU42336/93A patent/AU674852B2/en not_active Expired
- 1993-09-07 US US08/118,833 patent/US5342620A/en not_active Expired - Lifetime
-
1998
- 1998-12-04 HK HK98112850A patent/HK1011615A1/en not_active IP Right Cessation
-
2001
- 2001-09-27 JP JP2001297487A patent/JP3527721B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2230358A2 (en) * | 1973-05-25 | 1974-12-20 | Fisons Ltd | Cromoglycate contg. solns. - contg. a second therapeutically active cpd. e.g. an antihistamine |
| EP0109561A1 (en) * | 1982-10-27 | 1984-05-30 | Rorer International (Overseas) Inc. | Celiprolol for the treatment of glaucoma |
| EP0436726A1 (en) * | 1989-08-03 | 1991-07-17 | Eisai Co., Ltd. | Method of photostabilizing eyewash |
Cited By (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849253B2 (en) | 1992-05-06 | 2005-02-01 | Alcon Manufacturing, Ltd. | Use of borate-polyol complexes in ophthalmic compositions |
| US6143799A (en) * | 1992-05-06 | 2000-11-07 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| US6365636B1 (en) | 1992-05-06 | 2002-04-02 | Alcon Manufacturing, Ltd. | Use of borate-polyol complexes in ophthalmic compositions |
| US6503497B2 (en) | 1992-05-06 | 2003-01-07 | Alcon Manufacturing, Ltd. | Use of borate-polyol complexes in ophthalmic compositions |
| US5597559A (en) * | 1993-11-12 | 1997-01-28 | Ciba Geigy Corporation | Ophthalmic formulation |
| WO1995013050A1 (en) * | 1993-11-12 | 1995-05-18 | Ciba-Geigy Ag | Ophthalmic formulation useful in the treatment of dry eye syndrom |
| WO1996003484A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
| WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
| US5494937A (en) * | 1994-07-22 | 1996-02-27 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
| US5741817A (en) * | 1994-07-22 | 1998-04-21 | Chowhan; Masood | Use of low molecular weight amino acids in ophthalmic compositions |
| US8563011B2 (en) * | 1996-12-13 | 2013-10-22 | Alcon Research, Ltd. | Use of low molecular weight amino alcohols in ophthalmic compositions |
| EP0923950A2 (en) * | 1997-12-18 | 1999-06-23 | Tomey Corporation | Liquid agent for contact lens |
| EP0923950A3 (en) * | 1997-12-18 | 2000-12-27 | Tomey Corporation | Liquid agent for contact lens |
| EP2796138B1 (en) | 1998-09-30 | 2016-08-17 | Alcon Pharmaceuticals Limited | Antibiotic compositions for treatment of conjunctivitis |
| WO2003026420A1 (en) * | 2001-09-17 | 2003-04-03 | Menicon Co., Ltd. | Bactericidal solutions |
| WO2005093102A2 (en) * | 2004-03-11 | 2005-10-06 | Surmodics, Inc. | Array print buffers |
| WO2005093102A3 (en) * | 2004-03-11 | 2006-01-19 | Surmodics Inc | Array print buffers |
| EP1642568A1 (en) * | 2004-08-03 | 2006-04-05 | Prontomed GmbH | Mouthwash |
| EP2066300B1 (en) | 2006-09-28 | 2015-06-17 | Alcon Research, Ltd. | Self-preserved aqueous pharmaceutical compositions |
| EP2308466A1 (en) * | 2008-03-17 | 2011-04-13 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| EP2420223A1 (en) * | 2008-03-17 | 2012-02-22 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| EP2308466B1 (en) | 2008-03-17 | 2017-05-31 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| WO2009117242A3 (en) * | 2008-03-17 | 2010-02-04 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| EP2420223B1 (en) | 2008-03-17 | 2017-07-19 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| AU2009225931B2 (en) * | 2008-03-17 | 2014-03-13 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| AU2009225931B9 (en) * | 2008-03-17 | 2014-04-03 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| AU2009225931A9 (en) * | 2008-03-17 | 2014-04-17 | Novartis Ag | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| RU2494727C2 (en) * | 2008-06-09 | 2013-10-10 | Алькон, Инк. | Pharmaceutical composition containing fluoroquinolone antibiotic drug |
| WO2009151974A1 (en) * | 2008-06-09 | 2009-12-17 | Alcon Research, Ltd. | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| TWI495469B (en) * | 2008-06-09 | 2015-08-11 | Alcon Res Ltd | Improved pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| US9114168B2 (en) | 2008-06-09 | 2015-08-25 | Alcon Pharmacueticals Ltd. | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| US8450311B2 (en) | 2008-06-09 | 2013-05-28 | Novartis Ag | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| AU2009257778B2 (en) * | 2008-06-09 | 2014-09-11 | Alcon, Inc. | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| US8785497B2 (en) | 2009-04-17 | 2014-07-22 | Alcon Research, Ltd. | Aqueous ophthalmic compositions containing anionic therapeutic agents |
| US9044484B2 (en) | 2009-06-19 | 2015-06-02 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| EP2722035B1 (en) | 2009-06-19 | 2016-04-27 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| US9421265B2 (en) | 2009-06-19 | 2016-08-23 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
| WO2012026609A1 (en) | 2010-08-27 | 2012-03-01 | わかもと製薬株式会社 | Aqueous composition for ophthalmic administration |
| US11826347B2 (en) | 2018-03-27 | 2023-11-28 | Martin Uram | Anesthetic composition and method of anesthetizing the eye |
| EP3946311A4 (en) * | 2019-03-26 | 2022-12-28 | Martin Uram | Anesthetic composition and method of anesthetizing the eye |
| CN111821261A (en) * | 2019-07-23 | 2020-10-27 | 尼科斯眼药公司 | Method for preparing sterile ophthalmic aqueous fluticasone propionate A-type nanocrystal suspension |
| EP3769753A1 (en) | 2019-07-23 | 2021-01-27 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
| WO2021014348A1 (en) | 2019-07-23 | 2021-01-28 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
| CN111821261B (en) * | 2019-07-23 | 2022-07-26 | 尼科斯眼药公司 | Method for preparing sterile ophthalmic aqueous fluticasone propionate A-type nanocrystal suspension |
| US11406596B2 (en) | 2019-07-23 | 2022-08-09 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2132826C (en) | 1999-01-05 |
| AU674852B2 (en) | 1997-01-16 |
| DK0639070T3 (en) | 2005-11-28 |
| DE69333850T3 (en) | 2011-03-17 |
| JP3527721B2 (en) | 2004-05-17 |
| ATE300936T1 (en) | 2005-08-15 |
| DE69333850T2 (en) | 2006-01-12 |
| DE69333850D1 (en) | 2005-09-08 |
| JP2002177369A (en) | 2002-06-25 |
| ES2246491T5 (en) | 2011-01-31 |
| US5342620A (en) | 1994-08-30 |
| ES2246491T3 (en) | 2006-02-16 |
| AU4233693A (en) | 1993-11-29 |
| EP0639070B1 (en) | 2005-08-03 |
| EP0639070B2 (en) | 2010-09-08 |
| JPH07506377A (en) | 1995-07-13 |
| JP3337218B2 (en) | 2002-10-21 |
| HK1011615A1 (en) | 1999-07-16 |
| CA2132826A1 (en) | 1993-11-11 |
| EP0639070A1 (en) | 1995-02-22 |
| DK0639070T4 (en) | 2010-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5505953A (en) | Use of borate-polyol complexes in ophthalmic compositions | |
| EP0639070B1 (en) | Use of borate-polyol complexes in ophthalmic compositions | |
| EP1348427B1 (en) | Ophthalmic compositions containing galactomannan polymers and borate | |
| US8865776B2 (en) | Use of low molecular weight amino alcohols in ophthalmic compositions | |
| JP3361106B2 (en) | Conditioning solution for hard contact lens care | |
| KR0127768B1 (en) | Method and composition for disinfecting contact lenses | |
| US6180093B1 (en) | Method and composition for rewetting contact lenses and relieving eye dryness | |
| WO1996003158A1 (en) | Use of low molecular weight amino acids in ophthalmic compositions | |
| US20020018732A1 (en) | Preserving compositions containing chitosan and processes for making water soluble O-acetylated chitosan and chitosan | |
| US7364723B1 (en) | Liquid preparation for contact lenses | |
| EP1687037B1 (en) | Gentle and enhanced preservative systems | |
| JP2004530644A (en) | Artificial tear composition suitable for use with contact lenses | |
| KR20060111652A (en) | Gentle preservative compositions for self-preserving solutions | |
| EP1190718A2 (en) | Ophthalmic compositions comprising amino alcohols | |
| MXPA06006128A (en) | Gentle preservative compositions for self-preserving solutions | |
| MXPA06006127A (en) | Gentle and enhanced preservative systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993911061 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2132826 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993911061 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1993911061 Country of ref document: EP |